ANEB News and Press, Anebulo Pharmaceuticals Inc. From 09/13/21

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced the completion of finished product manufacturing of its lead drug ANE...

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced that managem...

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced the formatio...

Anebulo Pharmaceuticals (ANEB): FQ3 GAAP EPS of -$0.69.Cash and cash equivalents were $3.3M as of March 31, 2021.Press Release For further details see: Anebulo Pharmaceuticals reports FQ3 results

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid intoxication and substance addiction, today reported recent business...

Point Roberts, WA and Delta, BC - June 18, 2021 (Investorideas.com Newswire) Investorideas.com , a global news source and leading retail investor and trader resource, announces its weekly roundup of stocks to watch in Biotech and Mining. Today's stocks have been added to our lists of fr...

Eight IPOs and four SPACs went public this past week. The week's best performer, Sacramento bank Five Star Bancorp (FSBC) priced at the high end to raise $105 million at a $325 million market cap. Filing activity maintained a comfortable pace/remained moderate, with seven IPOs and...